ATLANTA — Drug maker UCB is seeking approval for one of its drugs as a stand-alone therapy for epilepsy.
The company said Monday that the Food and Drug Administration had accepted its regulatory approval application for Vimpat (lacosamide) for adult epilepsy patients with partial-onset seizures. The drug is already approved as an add-on therapy for partial-onset seizures in patients aged 17 and older.
"UCB has a strong heritage in epilepsy," UCB chief medical officer and EVP Iris Loew-Friedrich said. "The US filing for lacosamide in monotherapy is another step forward for people living with epilepsy."